CONTEXT: Previous studies of testosterone supplementation in HIV-infected men failed to demonstrate improvement in muscle strength. The effects of resistance exercise combined with testosterone supplementation in HIV-infected men are unknown. OBJECTIVE: To determine the effects of testosterone replacement with and without resistance exercise on muscle strength and body composition in HIV-infected men with low testosterone levels and weight loss. DESIGN AND SETTING:Placebo-controlled, double-blind, randomized clinical trial conducted from September 1995 to July 1998 at a general clinical research center. PARTICIPANTS: Sixty-one HIV-infected men aged 18 to 50 years with serum testosterone levels of less than 12.1 nmol/L (349 ng/dL) and weight loss of 5% or more in the previous 6 months, 49 of whom completed the study. INTERVENTIONS: Participants were randomly assigned to 1 of 4 groups: placebo, no exercise (n = 14); testosterone enanthate (100 mg/wk intramuscularly), no exercise (n = 17); placebo and exercise (n = 15); or testosterone and exercise (n = 15). Treatment duration was 16 weeks. MAIN OUTCOME MEASURES: Changes in muscle strength, body weight, thigh muscle volume, and lean body mass compared among the 4 treatment groups. RESULTS:Body weight increased significantly by 2.6 kg (P<.001) in men receiving testosterone alone and by 2.2 kg (P = .02) in men who exercised alone but did not change in men receiving placebo alone (-0.5 kg; P = .55) or testosterone and exercise (0.7 kg; P = .08). Men treated with testosterone alone, exercise alone, or both experienced significant increases in maximum voluntary muscle strength in leg press (range, 22%-30%), leg curls (range, 18%-36%), bench press (range, 19%-33%), and latissimus pulls (range, 17%-33%). Gains in strength in all exercise categories were greater in men assigned to the testosterone-exercise group or to the exercise-alone group than in those assigned to the placebo-alone group. There was a greater increase in thigh muscle volume in men receiving testosterone alone (mean change, 40 cm3; P<.001 vs zero change) or exercise alone (62 cm3; P = .003) than in men receiving placebo alone (5 cm3; P = .70). Average lean body mass increased by 2.3 kg (P = .004) and 2.6 kg (P<.001), respectively, in men who received testosterone alone or testosterone and exercise but did not change in men receiving placebo alone (0.9 kg; P = .21). Hemoglobin levels increased in men receiving testosterone but not in those receiving placebo. CONCLUSION: Our data suggest that testosterone and resistance exercise promote gains in body weight, muscle mass, muscle strength, and lean body mass in HIV-infected men with weight loss and low testosterone levels. Testosterone and exercise together did not produce greater gains than either intervention alone.
RCT Entities:
CONTEXT: Previous studies of testosterone supplementation in HIV-infectedmen failed to demonstrate improvement in muscle strength. The effects of resistance exercise combined with testosterone supplementation in HIV-infectedmen are unknown. OBJECTIVE: To determine the effects of testosterone replacement with and without resistance exercise on muscle strength and body composition in HIV-infectedmen with low testosterone levels and weight loss. DESIGN AND SETTING: Placebo-controlled, double-blind, randomized clinical trial conducted from September 1995 to July 1998 at a general clinical research center. PARTICIPANTS: Sixty-one HIV-infectedmen aged 18 to 50 years with serum testosterone levels of less than 12.1 nmol/L (349 ng/dL) and weight loss of 5% or more in the previous 6 months, 49 of whom completed the study. INTERVENTIONS:Participants were randomly assigned to 1 of 4 groups: placebo, no exercise (n = 14); testosterone enanthate (100 mg/wk intramuscularly), no exercise (n = 17); placebo and exercise (n = 15); or testosterone and exercise (n = 15). Treatment duration was 16 weeks. MAIN OUTCOME MEASURES: Changes in muscle strength, body weight, thigh muscle volume, and lean body mass compared among the 4 treatment groups. RESULTS: Body weight increased significantly by 2.6 kg (P<.001) in men receiving testosterone alone and by 2.2 kg (P = .02) in men who exercised alone but did not change in men receiving placebo alone (-0.5 kg; P = .55) or testosterone and exercise (0.7 kg; P = .08). Men treated with testosterone alone, exercise alone, or both experienced significant increases in maximum voluntary muscle strength in leg press (range, 22%-30%), leg curls (range, 18%-36%), bench press (range, 19%-33%), and latissimus pulls (range, 17%-33%). Gains in strength in all exercise categories were greater in men assigned to the testosterone-exercise group or to the exercise-alone group than in those assigned to the placebo-alone group. There was a greater increase in thigh muscle volume in men receiving testosterone alone (mean change, 40 cm3; P<.001 vs zero change) or exercise alone (62 cm3; P = .003) than in men receiving placebo alone (5 cm3; P = .70). Average lean body mass increased by 2.3 kg (P = .004) and 2.6 kg (P<.001), respectively, in men who received testosterone alone or testosterone and exercise but did not change in men receiving placebo alone (0.9 kg; P = .21). Hemoglobin levels increased in men receiving testosterone but not in those receiving placebo. CONCLUSION: Our data suggest that testosterone and resistance exercise promote gains in body weight, muscle mass, muscle strength, and lean body mass in HIV-infectedmen with weight loss and low testosterone levels. Testosterone and exercise together did not produce greater gains than either intervention alone.
Authors: A Strawford; T Barbieri; M Van Loan; E Parks; D Catlin; N Barton; R Neese; M Christiansen; J King; M K Hellerstein Journal: JAMA Date: 1999-04-14 Impact factor: 56.272
Authors: F R Sattler; S V Jaque; E T Schroeder; C Olson; M P Dube; C Martinez; W Briggs; R Horton; S Azen Journal: J Clin Endocrinol Metab Date: 1999-04 Impact factor: 5.958
Authors: I Sinha-Hikim; S Arver; G Beall; R Shen; M Guerrero; F Sattler; C Shikuma; J C Nelson; B M Landgren; N A Mazer; S Bhasin Journal: J Clin Endocrinol Metab Date: 1998-04 Impact factor: 5.958
Authors: A S Dobs; J Cofrancesco; W E Nolten; A Danoff; R Anderson; C D Hamilton; J Feinberg; D Seekins; B Yangco; F Rhame Journal: Am J Med Date: 1999-08 Impact factor: 4.965
Authors: A Strawford; T Barbieri; R Neese; M Van Loan; M Christiansen; R Hoh; G Sathyan; R Skowronski; J King; M Hellerstein Journal: J Acquir Immune Defic Syndr Hum Retrovirol Date: 1999-02-01
Authors: S Grinspoon; C Corcoran; H Askari; D Schoenfeld; L Wolf; B Burrows; M Walsh; D Hayden; K Parlman; E Anderson; N Basgoz; A Klibanski Journal: Ann Intern Med Date: 1998-07-01 Impact factor: 25.391
Authors: S Bhasin; T W Storer; N Asbel-Sethi; A Kilbourne; R Hays; I Sinha-Hikim; R Shen; S Arver; G Beall Journal: J Clin Endocrinol Metab Date: 1998-09 Impact factor: 5.958
Authors: Kishore M Lakshman; Beth Kaplan; Thomas G Travison; Shehzad Basaria; Philip E Knapp; Atam B Singh; Michael P LaValley; Norman A Mazer; Shalender Bhasin Journal: J Clin Endocrinol Metab Date: 2010-06-09 Impact factor: 5.958
Authors: Robin Haring; Thomas G Travison; Shalender Bhasin; Ramachandran S Vasan; Henri Wallaschofski; Maithili N Davda; Andrea Coviello; Joanne M Murabito Journal: J Clin Endocrinol Metab Date: 2011-09-21 Impact factor: 5.958
Authors: Matthew R Smith; Fred Saad; Blair Egerdie; Paul R Sieber; Teuvo L J Tammela; Chunlei Ke; Benjamin Z Leder; Carsten Goessl Journal: J Clin Oncol Date: 2012-05-29 Impact factor: 44.544